News from the Bench

Discover what’s going on at CST, receive our latest application notes and tips, read our science features, and learn about our products.

Subscribe

Antibody Guarantee

CST Antibody Performance Guarantee

LEARN MORE  

To Purchase # 9885S

9885S 1 mg

To get local purchase information on this product, click here

Questions?

Find answers on our FAQs page.

ANSWERS  

Visit PhosphoSitePlus®

PTM information and tools available.

LEARN MORE

Western blot analysis of extracts from HeLa cells treated with Roscovitine (20 μM) for the indicated times using Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb #2325 (left) or Phospho-(Ser) CDKs Substrate Antibody #2324 (right).

Learn more about how we get our images

Western blot analysis of extracts from HeLa cells treated with Roscovitine (20 μM) for the indicated times using an antibody to Rb.

Learn more about how we get our images
Image

Product Usage Information

Roscovitine [(R) stereoisomer] is supplied as a 1 mg powder. Store at or below -20ºC. Before use, dissolve powder in 143 μl DMSO or MeOH to make a 20 mM stock solution. The suggested working concentration is 20 μM in tissue culture medium. Treat cells for 4-24 hours. Store solution at -20ºC.


Storage: Store lyophilized or in solution at -20ºC, desiccated. In lyophilized form, the chemical is stable for 24 months. Once in solution, use within 3 months to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Product Description

Molecular Weight:

354.46 g/mol


Purity:

>99%


Molecular Formula:

C19H28N6O


Roscovitine is a cell permeable reversible selective inhibitor of cyclin-dependent kinases CDK1 (cdc2), CDK2 and CDK5 (1). A purine analog, this drug competes for the binding site of ATP in the catalytic cleft. Treatment of cultured cells with roscovitine can cause cell cycle arrest or apoptosis (1-4). The IC50 for cdc2 activity is 0.65 μM in vitro (1).


1.  Meijer, L. et al. (1997) Eur J Biochem 243, 527-36.

2.  Whittaker, S.R. et al. (2007) Cell Cycle 6, 3114-31.

3.  Dey, A. et al. (2008) Cell Death Differ 15, 263-73.

4.  Wojciechowski, J. et al. (2003) Int J Cancer 106, 486-95.



For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.